Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Average Recommendation of “Moderate Buy” from Brokerages

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has received an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $40.8571.

A number of equities analysts recently commented on LYEL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Friday, July 17th. Royal Bank Of Canada set a $34.00 target price on Lyell Immunopharma in a research report on Friday, August 14th. Zacks Research raised Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a research report on Monday, May 18th. B. Riley Financial initiated coverage on Lyell Immunopharma in a research note on Wednesday, July 22nd. They set a “buy” rating and a $44.00 price objective for the company. Finally, Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th.

Lyell Immunopharma Stock Performance

NASDAQ LYEL opened at $14.37 on Monday. The company has a market capitalization of $352.06 million, a price-to-earnings ratio of -1.12 and a beta of -0.04. The company’s 50-day simple moving average is $14.10 and its two-hundred day simple moving average is $17.59. Lyell Immunopharma has a one year low of $11.47 and a one year high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.92) earnings per share for the quarter, topping the consensus estimate of ($1.94) by $0.02. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. The firm had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $0.00 million. Equities analysts expect that Lyell Immunopharma will post -7.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

Hedge funds and other institutional investors have recently bought and sold shares of the company. Velan Capital Investment Management LP boosted its stake in Lyell Immunopharma by 2.9% in the second quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company’s stock valued at $1,475,000 after acquiring an additional 3,000 shares in the last quarter. venBio Partners LLC acquired a new position in shares of Lyell Immunopharma during the second quarter worth $4,744,643. Bank of New York Mellon Corp acquired a new position in shares of Lyell Immunopharma during the second quarter worth $347,000. Bank of America Corp DE lifted its holdings in shares of Lyell Immunopharma by 314.2% during the 1st quarter. Bank of America Corp DE now owns 33,321 shares of the company’s stock valued at $668,000 after purchasing an additional 25,276 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Lyell Immunopharma by 194.8% in the 1st quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock worth $2,335,000 after purchasing an additional 76,921 shares in the last quarter. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.